Aspirin and COX-2 inhibitor use in patients with stage III colon cancer.

  title={Aspirin and COX-2 inhibitor use in patients with stage III colon cancer.},
  author={Kimmie Ng and Jeffrey A. Meyerhardt and Andrew T. Chan and Kaori Sato and Jennifer A W Chan and Donna Niedzwiecki and Leonard Saltz and Robert J. Mayer and Al Bowen Benson and Paul L. Schaefer and Renaud Whittom and Alexander Hantel and Richard M. Goldberg and Alan Paul Venook and Shuji Ogino and Edward L. Giovannucci and Charles S. Fuchs},
  journal={Journal of the National Cancer Institute},
  volume={107 1},
We conducted a prospective, observational study of aspirin and COX-2 inhibitor use and survival in stage III colon cancer patients enrolled in an adjuvant chemotherapy trial. Among 799 eligible patients, aspirin use was associated with improved recurrence-free survival (RFS) (multivariable hazard ratio [HR] = 0.51, 95% confidence interval [CI] = 0.28 to 0.95), disease-free survival (DFS) (HR = 0.68, 95% CI = 0.42 to 1.11), and overall survival (OS) (HR = 0.63, 95% CI = 0.35 to 1.12). Adjusted… CONTINUE READING
37 Citations
41 References
Similar Papers


Publications citing this paper.
Showing 1-10 of 37 extracted citations


Publications referenced by this paper.
Showing 1-10 of 41 references

Similar Papers

Loading similar papers…